Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company focused on targeted protein degradation, and its news flow reflects active clinical development, collaborations and capital markets activity. Company updates frequently highlight progress with cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and certain lymphomas, as well as broader pipeline and platform achievements.
News for C4 Therapeutics often centers on clinical data milestones, such as Phase 1 results for cemsidomide in combination with dexamethasone, acceptance of data for oral presentation at scientific meetings, and plans for registrational trials like the Phase 2 MOMENTUM study. Releases also cover developments in non-Hodgkins lymphoma cohorts and updates on other degrader programs, including CFT8919 for EGFR-mutant non-small cell lung cancer and CFT1946 for BRAF V600 mutant solid tumors.
Investors following CCCC news will also see collaboration announcements and research milestones. Examples include the clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide with elranatamab in multiple myeloma, milestone achievements in partnerships with Biogen, Roche and Merck KGaA, Darmstadt, Germany, and regulatory steps such as IND acceptance for BIIB142, an IRAK4 degrader designed by C4 Therapeutics.
Financial and corporate updates are another key news category. The company regularly reports quarterly financial results, cash runway guidance, equity offerings and changes to its capital structure via press releases and Form 8-K filings. For readers tracking CCCC, this news page aggregates these clinical, scientific, collaboration and financing updates in one place, making it easier to monitor how C4 Therapeutics is advancing its targeted protein degradation pipeline over time.
C4 Therapeutics reported significant advancements and financial results for 2021, including total revenue of $45.8 million, up from $33.2 million in 2020, primarily due to collaboration agreements. Despite a net loss of $83.9 million, the net loss per share improved to $1.82 from $5.83. The company anticipates its cash reserves of $451.5 million will sustain operations through 2024. Upcoming presentations at the AACR Annual Meeting will showcase clinical data on the CFT7455 trial for hematologic malignancies and pre-clinical data on novel candidates.
C4 Therapeutics (Nasdaq: CCCC) announced key milestones for 2022, including expected initial data for CFT7455, a novel degrader for multiple myeloma and lymphomas. The FDA granted IND clearance for CFT8634, allowing the initiation of its Phase 1 trial in synovial sarcoma. Additionally, CFT1946, targeting BRAF V600X, will enter trials in 2H 2022. With approximately $450 million in cash expected to last until late 2024, the company is poised for growth and innovation.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. EST. This conference emphasizes the company's innovative approach to developing small-molecule medicines that selectively degrade disease-causing proteins.
The live webcast can be viewed on the company's website, with a replay available for two weeks post-event. C4 Therapeutics focuses on targeted protein degradation to improve treatment options for cancer and other diseases.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has been included in the NASDAQ Biotechnology Index, effective December 20, 2021. This index tracks notable biotechnology and pharmaceutical companies listed on NASDAQ, requiring eligibility criteria such as minimum market capitalization and average daily trading volume of 100,000 shares. C4 Therapeutics focuses on developing drugs that selectively degrade disease-causing proteins, offering advantages like reduced drug resistance and side effects. The company aims to target cancer and other diseases.
C4 Therapeutics (Nasdaq: CCCC) reported Q3 2021 revenue of $8.5 million, slightly up from $8.4 million YoY. R&D expenses rose to $24.3 million from $23.9 million, driven by pre-clinical costs. G&A expenses surged to $8.5 million from $2.9 million, mainly due to stock-based compensation and professional fees. A net loss of $24.7 million was recorded, with net loss per share at $0.51. The company anticipates submitting an IND application for CFT8634 by year-end 2021 and aims to deliver four clinical programs by the end of 2022.
C4 Therapeutics (Nasdaq: CCCC) reported significant advancements in their clinical programs and financials for Q2 2021. They initiated the Phase 1/2 trial of CFT7455 for hematologic malignancies and received Orphan Drug Designation from the FDA for this therapy. The company reported Q2 revenue of $9.8 million, a slight increase from $9.7 million in the previous year, and a net loss of $22.6 million, up from $10.8 million. A successful public offering yielded $180.8 million, bolstering cash reserves to approximately $499 million by June 30, 2021, supporting their ambitious clinical development plans.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced that the FDA granted orphan drug designation to its drug CFT7455 for treating multiple myeloma. This designation supports clinical development and provides potential market exclusivity in the U.S. Moreover, CFT7455 is designed to selectively target disease-causing proteins, with an ongoing Phase 1/2 trial aimed at evaluating its safety and anti-tumor activity, intending to enroll approximately 160 patients. C4 Therapeutics aims to improve outcomes for multiple myeloma patients who currently face limited treatment options.
C4 Therapeutics (Nasdaq: CCCC) announced the closing of an underwritten public offering of 4,887,500 shares at $37.00 per share, raising about $180.8 million in gross proceeds. This includes the full exercise of the underwriters' option for an additional 637,500 shares. The offering was managed by J.P. Morgan, Jefferies, Evercore ISI, BMO Capital Markets, and UBS Investment Bank. The funds will be directed towards advancing the company’s innovative small-molecule medicines aimed at degrading disease-causing proteins, a strategy that could potentially enhance cancer treatments.
C4 Therapeutics (Nasdaq: CCCC) presented promising pre-clinical data for its lead compound, CFT7455, at the ICML conference. This orally bioavailable MonoDAC™ demonstrated high binding affinity to cereblon and effective IKZF1/3 degradation in non-Hodgkin’s lymphoma (NHL) models. CFT7455 showed superior efficacy in xenograft models compared to approved therapies, including significant tumor regressions in various NHL subtypes. The Phase 1/2 trial, initiated in June 2021, aims to further assess CFT7455’s potential against multiple myeloma and NHLs, with top-line results expected in 2022.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has announced the pricing of a public offering of 4.25 million shares of common stock at $37.00 each. The offering, expected to yield approximately $157 million in gross proceeds, is set to close around June 21, 2021, pending customary conditions. An option for underwriters to purchase an additional 637,500 shares is included. J.P. Morgan, Jefferies, and other banks are managing the offering. C4T focuses on targeted protein degradation therapies for cancer and other diseases.